4.080SEK-0.49%Mkt Cap: 87.14M SEKP/E: —Last update: 2026-05-13
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)1.76
PEG—
P/B0.22
P/S0.30
EV/EBITDA-15.71
EV/Revenue1.46
EPS (TTM)-7.74
EPS (Forward)2.40
Cash Flow & Leverage
FCF Yield3.72%
FCF Margin1.13%
Operating CF-31.93M SEK
CapEx (TTM)—
Net Debt/EBITDA-12.45
Net Debt332.59M SEK
Technical
SMA 505.231 (-22.0%)
SMA 20014.21 (-71.3%)
Beta0.51
S&P 52W Chg24.23%
Avg Vol (30d)6.56K
Avg Vol (10d)4.06K
Technical Indicators
RSI (14)33.6
MACD-0.3801
MACD Signal-0.4659
MACD Hist.+0.0858
BB Upper4.779 SEK
BB Middle4.338 SEK
BB Lower3.897 SEK
BB Width20.34%
ATR (14)0.1995 SEK
Vol Ratio (20d)0.00x
52W Range
3.6802% of range30.00
52W High30.00 SEK
52W Low3.680 SEK
Profitability
Gross Margin82.15%
EBITDA Margin-9.29%
Profit Margin-56.51%
Oper. Margin-158.52%
ROE-40.39%
ROA-17.55%
Revenue Growth-14.50%
Earnings Growth—
Balance Sheet
Debt/Equity0.87
Current Ratio1.37
Quick Ratio0.69
Book Value/Sh19.17 SEK
Cash/Share0.6580 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.20.65M
Float11.84M
Insiders29.43%
Institutions0.01%
Analyst Consensus
Rating—
Target (Mean)25.00 SEK
Target Range25.00 SEK – 25.00 SEK
# Analysts1
Company
Market Cap87.14M SEK
Enterprise Value419.73M SEK
Revenue (TTM)287.55M SEK
Gross Profit232.43M SEK
Net Income (TTM)-159.88M SEK
Revenue/Share13.93 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees140
Last Price4.080 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—